Management of guillain-barré syndrome-an autoimmune disorder: A review.

Loading...
Thumbnail Image
Date
2010-08
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Guillain-Barré syndrome is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances, the weakness and abnormal sensations spread to the arms and upper body. There is no known cure for Guillain-Barré syndrome, but therapies can lessen the severity of the illness and accelerate the recovery in most patients. There are also a number of ways to treat the complications of the disease. Currently, plasmapheresis and high-dose immunoglobulin therapy are used. Plasmapheresis seems to reduce the severity and duration of the Guillain-Barré episode. In high-dose immunoglobulin therapy, doctors give intravenous injections of the proteins that in small quantities, the immune system uses naturally to attack invading organism. The most critical part of the treatment for this syndrome consists of keeping the patient's body functioning during recovery of the nervous system. This can sometimes require placing the patient on a respirator, a heart monitor, or other machines that assist body function. The aim of present article is to provide in depth knowledge about Guillain-Barré syndrome which is no doubt, a rare autoimmune disorder. In this article the author has explained all the clinical aspects related to Guillain-Barré syndrome. This article presents a brief review of Guillain-Barré syndrome with an emphasis on its possible management and therapies.
Description
Keywords
Autoimmune Disorder, Guillain–Barré syndrome, GBS, AIDP, Landry's paralysis, peripheral neuropathies
Citation
Raghvendra, Tyagi Satyanand, Yadav Pramod, Saxena Sunanda. Management of guillain-barré syndrome-an autoimmune disorder: A review. International Journal of Applied Biology and Pharmaceutical Technology. 2010 Aug-Oct; 1(2): 722-728.